EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review

Carmine De Luca iD, Paola Ciciola, Guido D'Errico, Maria Donata Di Taranto iD, Giuliana Fortunato iD, Carina Gross, Jonathan Garn, Gabriella Iannuzzo iD, Matteo Di Minno iD, Ilenia Calcaterra

Genes · 2025

DOI: 10.3390/genes16111377 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Genes, 2025. Verfasst von Carmine De Luca und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy. Hauptthemen laut MEDLINE: Hypertriglyceridemia, Hyperlipoproteinemia Type I. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Istruzione e del Merito, Italian Ministry of University and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Severe hypertriglyceridemia (SHTG) is associated with acute pancreatitis, metabolic dysfunction, and increased cardiovascular risk. Its genetic architecture ranges from rare biallelic variants causing familial chylomicronemia syndrome (FCS) to more prevalent polygenic or multifactorial chylomicronemia syndromes (MCS).

Methods

We systematically reviewed scientific literature up to 2025 for studies reporting genetic data, clinical features, or therapeutic outcomes in adults with triglycerides (TG) ≥ 500 mg/dL. Extracted data were synthesized for genotype, polygenic risk score (PRS), TG levels, metabolic comorbidities, hepatic steatosis, pancreatitis, and treatment response.

Results

Ten studies (n = 2521) were included. FCS due to biallelic LPL, APOC2, GPIHBP1, or LMF1 variants accounted for 2800 mg/dL) with pancreatitis prevalence (>70%). APOA5, APOC3, and APOB variants were associated with intermediate TG levels and high rates of metabolic dysfunction-associated steatotic liver disease (MASLD). Polygenic hypertriglyceridemia represented ~70–80% of cases, with TG ≈ 2200 mg/dL and pancreatitis prevalence 15–20%, largely modulated by metabolic triggers. MASLD was present in >70% of polygenic cases, supporting a “two-hit” model where hepatic overproduction of TG-rich lipoproteins amplifies TG excess. Interventional trials demonstrated TG reductions with APOC3 antisense therapy (70–80%) and ANGPTL3 inhibition (50–55%), while GLP-1RA significantly reduced hepatic fat (30–35%) and resolved NASH in up to 59% of patients.

Conclusions

SHTG displays a genotype–phenotype gradient: FCS is linked to recurrent pancreatitis, whereas polygenic/MCS forms are closely associated with MASLD and metabolic dysfunction. These findings support a precision-medicine approach integrating genetic testing and PRS-guided strategies—prioritizing APOC3/ANGPTL3 inhibitors for FCS and combined TG-lowering plus metabolic therapies for MCS—to reduce pancreatitis recurrence and liver disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertriglyceridemiaHyperlipoproteinemia Type IHumansLipoprotein LipasePancreatitisTriglyceridesReceptors, LipoproteinApolipoprotein C-IIIApolipoprotein C-IIAngiopoietin-Like Protein 3Membrane Proteins

Stichwörter der Autor:innen

familial chylomicronemia syndrome (FCS)metabolic dysfunction-associated steatotic liver disease (MASLD)polygenic hypertriglyceridemiaprecision medicinesevere hypertriglyceridemia

Substanzen

Lipoprotein LipaseTriglyceridesGPIHBP1 protein, humanLMF1 protein, humanReceptors, LipoproteinApolipoprotein C-IIIANGPTL3 protein, humanApolipoprotein C-IILPL protein, humanAngiopoietin-Like Protein 3

Autor:innen und Institutionen

  • Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy.
  • Department of Molecular Medicine and Medical Biotechnologies, CEINGE Advanced Biotechnologies S.C. A R.L, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy.
  • Faculty of Medicine, Hannover Medical School (MHH), 30625 Hannover, Germany.

ORCID-Profile: Carmine De Luca, Maria Donata Di Taranto, Giuliana Fortunato, Gabriella Iannuzzo, Matteo Di Minno

Förderung

  • Ministero dell'Istruzione e del Merito
  • Italian Ministry of University and Research

Zitieren

APA

De Luca, C., Ciciola, P., D'Errico, G., Di Taranto, M. D., Fortunato, G., Gross, C., Garn, J., Iannuzzo, G., Di Minno, M., & Calcaterra, I. (2025). Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review. Genes. https://doi.org/10.3390/genes16111377

Vancouver

De Luca C, Ciciola P, D'Errico G, Di Taranto MD, Fortunato G, Gross C, et al. Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review. Genes. 2025. doi:10.3390/genes16111377

BibTeX
@article{DeLuca2025,
  author = {De Luca, Carmine and Ciciola, Paola and D'Errico, Guido and Di Taranto, Maria Donata and Fortunato, Giuliana and Gross, Carina and Garn, Jonathan and Iannuzzo, Gabriella and Di Minno, Matteo and Calcaterra, Ilenia},
  title = {Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16111377}
}
Kostenlos starten →